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Abstract
Genome-wide association studies (GWAS) have identified dozens of common genetic vari-
ants associated with risk of colorectal cancer (CRC). However, the majority of CRC heritabil-
ity remains unclear. In order to discover low-frequency, high-risk CRC susceptibility variants
in Swedish population, we genotyped 1 515 CRC patients enriched for familial cases, and
12 108 controls. Case/control association analysis suggested eight novel variants associ-
ated with CRC risk (OR 2.0–17.6, p-value < 2.0E-07), comprised of seven coding variants in
genes RAB11FIP5, POTEA, COL27A1, MUC5B, PSMA8, MYH7B, and PABPC1L as well
as one variant downstream of NEU1 gene. We also confirmed 27 out of 30 risk variants pre-
viously reported from GWAS in CRC with a mixed European population background. This
study identified rare, coding sequence variants associated with CRC risk through analysis in
a relatively homogeneous population. The segregation data suggest a complex mode of
inheritance in seemingly dominant pedigrees.
Introduction
Colorectal cancer (CRC) remains a major source of cancer morbidity and mortality, as it
accounts for the fourth most common cause of cancer deaths worldwide [1]. In Sweden 20%
of new cases have at least one close relative with CRC and their family members are at
increased risk of the disease [2]. Since CRC is considered to develop over precursor lesions
detectable and removable in risk-individuals under surveillance, it is important to identify sub-
jects at increased risk [3]. Less than 5% of all CRC represent high-penetrant CRC syndromes,
most commonly familial adenomatous polyposis (FAP) or Lynch syndrome [2, 4].
High-risk genes have typically been identified via linkage analysis in large pedigrees or
sequencing of candidate genes [5–7], and more recently also by next-generation sequencing
(NGS) [4, 8–10]. Genome-wide association studies (GWAS) using chip-based techniques have
been applied to study common genetic variants in order to find out the proportion of their
contribution to the CRC risk. To date, less than 100 CRC susceptibility variants have been
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identified across less than 50 chromosomal regions [11–14], however, in total these SNPs and
their surrounding regions represent no more than 2% of the heritability of CRC [15], and typi-
cally, each with a small increased risk (OR< 2).
Thus, a substantial risk is still to be explained since the genetic contribution to CRC is esti-
mated to 35% [16]. The existence of rare high-risk alleles has been hypothesized [17]. In order
to test the hypothesis that CRC risk was associated with variations within gene coding
sequence, Illumina exome array was used in association studies. The studies used over 12 000
cases and more than twice as many controls from six different European populations, mostly
from UK [18]. Some additional novel common CRC low-risk loci were suggested [18]. There
is a substantial variation in the frequency of various single nucleotide polymorphisms (SNPs)
between populations and even within populations [19, 20]. The vast majority of this associa-
tion study included the heterogeneous population in England mixed with the more homoge-
neous population from Scotland, plus four other European populations [18]. In this work, a
different study was designed in order to maximize the likelihood of finding rare high- or mod-
erate risk genes. The new study used a more homogeneous population from Sweden and
focused mostly on familial cases.
Materials and methods
Study subjects
Two hundred and sixty-two familial CRC cases were first recruited from families undergoing
genetic counselling at the department of Clinical Genetics, Karolinska University Hospital,
during the years 1990–2010. Another 1 253 cases were from a cohort of more than 3 300 conse-
cutive patients operated on for CRC in 14 hospitals in and around Stockholm and Uppsala
between 2004 and 2009 and were included in the Swedish Colorectal Cancer Low-risk Study
[2]. FAP and Lynch syndrome were excluded using medical records and our current clinical
protocol [2, 21], respectively. Cancer in first- and second-degree relatives and cousins was
recorded, and pedigrees for the families of the index-person (the patient) were constructed. All
diagnoses in family members, which suggested possible CRC, were verified using medical rec-
ords or death certificates [2]. Altogether, 936 familial CRC cases, who had at least one first-
degree relative with CRC, as well as 579 sporadic CRC cases were included in this study. All
patients gave written informed consents in accordance with Swedish legislation and the study
was approved by the Regional Ethics Committee in Stockholm, Dnr: 02–489 and 16/24-31/1.
As controls we used 18 560 twins from the Swedish Twin Registry [22] that were genotyped
using the same platform during 2014–2015. The majority of twins were from the Child and
Adolescent Twin Study in Sweden (CATSS), which is an ongoing longitudinal twin study tar-
geting all twins born in Sweden since 1993. Other studies from the Swedish Twin Registry also
had samples genotyped using the same platform, therefore are included in this analysis as well.
In short, phenotypic data on cancer had previously been obtained through linking the twins to
the Swedish Cancer Registry using the unique person identification number available for all
Swedish citizens. Only one twin from each twin pair where none was affected was considered
eligible for serving as control in the association analysis.
Genotyping quality control (QC)
Genotyping of 1 515 CRC samples was performed on Infinium Human Exome BeadChip
12v1.0 (containing 247 870 genetic markers, Illumina Inc., San Diego, CA) and called using
the corresponding Illumina GenCall algorithm. 16 748 markers and 31 individuals were
excluded due to call rate less than 90%.
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18 560 individuals from the Swedish Twin Registry (all available dizygotic twins and one
twin in each pair of monozygotic twins) were genotyped using the Illumina Infinium PsychAr-
ray-24 BeadChip (containing 588 628 genetic markers, Illumina Inc., San Diego, CA) at the
SNP&SEQ Technology Platform in Uppsala, Sweden. Variant calling was performed using
Illumina GenCall algorithm for common variants and zCall [23] for rare variants. Genotyping
results for 18 193 subjects on 569 211 markers passed the initial pre-processing quality assur-
ance. In further QC, markers were excluded if call rate was< 0.98 (3 827 markers), cross-
batch discordance was > 10% (102 markers), with more than one discordant genotype within
monozygotic twin pairs (323 markers), deviated significantly from Hardy-Weinberg equilib-
rium (p-value < 1E-06, 2 399 markers), with allele frequency differed by> 10% (absolute dif-
ference) from that of 1000 Genomes European samples and mean GenCall scores < 0.5 (6
markers), significantly associated with more than one genotyping batch (p-value < 5E-08, 35
markers), or on Y-chromosome or mitochondria due to poor calling (1 332 markers). Samples
were excluded in case of genotyping success rate< 98% (4 samples), abnormal heterozygosity
(autosomal inbreeding coefficient F outside ± 0.2, 7 samples), possible sample contamination
(sample relatedness> 6 standard deviations from mean in 1 000 random samples, 14 samples),
gender discrepancy between reported and X-chromosome heterozygosity-predicted (22 sam-
ples), or evidence of non-European ancestry (> 6 standard deviations from the mean values of
the first two principal components in 1000 Genomes European populations, 248 samples). 17
898 (98%) individuals and 561 187 (98%) markers passed QC.
Genotyping data of the two platforms were merged on 223 917 genetic markers that are
present on both platforms. 41 markers with call rate< 98% in the merged dataset and 2 234
markers with significant deviation from Hardy-Weinberg equilibrium (p-value < 0.001) were
further removed. Population stratification was addressed on the merged dataset using PLINK
[24] and 363 individuals with evidence of being population outliers based on multidimensional
scaling (MDS) analysis were excluded (S1 Fig). Only one twin from each twin pair where none
was affected was considered eligible for serving as control in the association analysis. It was
further noticed that 48 CRC samples harbored a higher than expected number of rare variants,
which were subsequently excluded. Finally, a total of 13 496 individuals, including 1 388 cases
and 12 108 controls remained qualified for the association analysis.
Statistical analysis
The association between allelic dosage for all variants that passed the stringent quality control
procedures and CRC status was calculated using standard case/control association analysis in
PLINK (command line: plink—assoc) [24].
Sequencing validation
All candidate risk variants suggested by the statistical analysis were subjected to Sanger
sequencing verification in the respective CRC cases. False risk alleles caused by incorrect geno-
typing were subsequently removed. Available family members of confirmed risk variant carri-
ers were also tested for the same variant by Sanger sequencing to investigate variant
segregation in the family.
Results
Post QC exome-wide association analysis was carried out on 1 388 cases and 12 108 controls
using 221 642 genetic markers. 79 496 of the markers were monomorphic and 109 616 markers
were rare variants (minor allele frequency (MAF) < 1%). The experiment was set up to search
for rare alleles with an increased risk of CRC. Thirty-nine markers were observed with the
Rare variants associated with Swedish CRC
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minor allele associated with a statistically significantly elevated risk exceeding Bonferroni-cor-
rected exome-wide threshold (p-value < 2.24E-07). Seven markers were removed due to
cross-platform base-calling errors, and Sanger sequencing was performed on all suggested
mutation carriers of the remaining 32 markers and confirmed the genotyping results of eight
variants (Table 1). All the eight variants were rare (allele frequency < 1% in controls) and asso-
ciated with moderate risks (OR> 2). Seven of the eight variants were missense variants in
genes RAB11FIP5,POTEA, COL27A1,MUC5B, PSMA8, MYH7B, and PABPC1L, whereas the
other was a downstream variant close to the gene NEU1 (Table 2). Six of the exonic variants
were predicted to be pathogenic by at least one functional inference tool (Table 2). Three of
the SNPs could be tested in available family members in four families and segregated more or
less with CRC or adenomas in the families (Fig 1).
We compared our results with the findings in a previous study [18]. Among the 30 previ-
ously reported risk SNPs comprising of 15 statistically significant markers and 15 markers
with less evidence, 27 were confirmed with an increased risk (OR> 1), including all 15 signifi-
cant risk variants and 12 out of 15 variants that did not reach the significance threshold
(Table 3).
To further study the possibility that the eight SNPs are not pathogenic per se, but rather
associated with other pathogenic SNPs in adjacent regions, we selected eight additional mark-
ers among all SNPs located within 1 Mb distance from the eight original risk alleles based on
their risk and significance (p-value < 3E-05) for further investigation. Sanger sequencing
Table 1. Candidate risk variants identified in GWAS confirmed by Sanger sequencing.
SNP Chr Position Ref allele Risk allele Allele count
Risk / Ref
Risk allele
frequency
OR P-value MAF
Case Control Case Control SweGen ExAC
All
ExAC
NFE
1000G
All
1000G
EUR
rs148220987 2 73315364 C A 13 / 2763 18 / 24188 0.47% 0.07% 6.3 6.5E-09 0.4% 0.18% 0.11% 0.1% 0.4%
rs12193504 6 31820805 G A 42 / 2714 180 / 23796 1.52% 0.75% 2.0 3.2E-08 1.6% - - 5.3% 3.8%
rs202238834 8 43152442 A G 3 / 2687 0 / 24216 0.11% 0% - 2.0E-07 - 0.01% 0.01% - -
rs34578955 9 116930628 G A 4 / 2768 0 / 24216 0.14% 0% - 3.4E-09 0.05% 0.53% 0.03% 1.5% 0.1%
rs200554635 11 1267115 C A 8 / 2766 20 / 24196 0.29% 0.08% 3.5 3.6E-08 0.1% 0.23% 0.35% 0.2% 0.6%
rs137990346 18 23731909 A G 4 / 2772 0 / 24216 0.14% 0% - 3.5E-09 0.1% 0.03% 0.05% 0.04% 0.1%
rs754511 20 33575677 T A 29 / 2747 70 / 24132 1.04% 0.29% 3.6 4.5E-10 1.1% 0.63% 1.02% 0.3% 1.3%
rs201302413 20 43547582 A C 10 / 2752 5 / 24211 0.36% 0.02% 17.6 5.5E-13 0.3% 0.27% 0.31% 0.04% 0.1%
MAF was extracted from the SweGen (https://swegen-exac.nbis.se/), ExAC (http://exac.broadinstitute.org/) and 1000Genomes (http://www.internationalgenome.org/)
databases (date of access: 2017-11-07). NFE, non-Finnish European; EUR, European.
https://doi.org/10.1371/journal.pone.0193547.t001
Table 2. Functional prediction of validated risk variants.
SNP Gene AA change PolyPhen [25] SIFT [26] LRT [27] MutationTaster [28] Mutation Assessor [29] FATHMM [30]
rs148220987 RAB11FIP5 R461L Probably damaging Tolerated Deleterious Disease causing Medium Tolerated
rs12193504 NEU1 (Downstream) - - - - - - -
rs202238834 POTEA Q143R Benign Tolerated Neutral - Neutral Tolerated
rs34578955 COL27A1 A265T Benign Tolerated - Polymorphism Medium Damaging
rs200554635 MUC5B T3002K Probably damaging NA - Polymorphism Low Tolerated
rs137990346 PSMA8 V112A Possibly damaging Damaging Deleterious Disease causing Medium Tolerated
rs754511 MYH7B F501Y Probably damaging Tolerated Neutral Disease causing Medium Damaging
rs201302413 PABPC1L E180A Possibly damaging Damaging Deleterious Disease causing Low Damaging
https://doi.org/10.1371/journal.pone.0193547.t002
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confirmed the genotyping results in three of the eight markers, located in genes ALMS1,
COL27A1 and HNF4A, respectively (Table 4).
Discussion
Our previous study, testing a heterogeneous population of unselected CRC patients and con-
trols with the Illumina exome chip, confirmed some of the more common risk alleles and was
able to suggest 30 new ones, with frequencies between 10–50% and ORs typical for the low-
risk allele pattern of 1.1–1.3 [18]. The present study interrogating a more homogeneous popu-
lation with a selection of mostly familial CRC patients demonstrated eight novel rare moder-
ate-risk loci confirming the hypothesis of existing rare moderate-risk alleles associated with
cancer (allele frequencies below 1% and ORs 2.0–17.6). Seven of the variants were missense
mutations in seven different genes, RAB11FIP5,POTEA, COL27A1,MUC5B, PSMA8, MYH7B
and PABPC1L, and one was in the downstream region of NEU1 (Tables 1 and 2).
None of these eight SNPs were found in our previous study [18]. This is likely due to the
fact that the first study used unselected cases and the second mostly familial cases, thus more
likely to demonstrate rare moderate-risk alleles. The suggested SNPs were mostly exonic and
could constitute pathogenic SNPs. However, it is still possible that the SNP is only associated
with another pathogenic SNP in its vicinity, and probably targeting the same gene and if so, it
cannot be replicated easily using different populations. Findings from a study using mixed
populations should be more likely able to be replicated in any population, and, in fact, we in
the current study managed to confirm 27 of 30 suggested SNPs from our first paper (Table 3).
Fig 1. Pedigrees of the families tested for variant segregation. Mutation carriers and non-carriers are indicated with red and green squares, respectively. Diagnosis
and age (when available) is indicated under each individual in bold text, and sample IDs in Italic. CRC, colorectal cancer; HP, hyperplastic polyp; GaCa, gastric cancer;
TVAHD, tubulovillous adenoma with high degree dysplasia; BrCa, breast cancer; TVA, tubulovillous adenoma; SALD, serrated adenomas with low degree dysplasia.
https://doi.org/10.1371/journal.pone.0193547.g001
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Another reason for not observing the eight SNPs in the previous study could be that these
eight SNPs were not successfully genotyped within the first study. Studies using very rare SNPs
Table 3. Comparison of previously reported risk variants [18] to the current study.
SNP Position Gene Ref allele Risk allele Previous report [18] This study
Freq in case Freq in ctrl OR P-value Freq in case Freq in ctrl OR P-value
rs6687758 1:222164948 A G 0.22 0.2 1.1 3.2E-11 0.23 0.20 1.17 8.8E-04
rs16892766 8:117630683 A C 0.1 0.08 1.3 3.6E-17 0.11 0.10 1.16 1.7E-02
rs16888728 8:117783975 UTP23 G A 0.11 0.1 1.2 1.4E-07 0.11 0.11 1.03 6.9E-01
rs10505477 8:128407443 G A 0.55 0.51 1.2 2.1E-21 0.53 0.51 1.11 1.0E-02
rs6983267 8:128413305 A C 0.56 0.52 1.2 1.1E-27 0.54 0.52 1.10 2.0E-02
rs7014346 8:128424792 G A 0.41 0.37 1.2 4.2E-24 0.38 0.36 1.12 5.8E-03
rs6580742 12:50727811 FAM186A G A 0.2 0.19 1.1 1.2E-07 0.18 0.17 1.07 1.7E-01
rs12303082 12:50754563 FAM186A C A 0.37 0.35 1.1 7.4E-08 0.34 0.32 1.09 3.8E-02
rs1129406 12:51203371 ATF1 G A 0.43 0.4 1.1 8.3E-09 0.40 0.38 1.08 5.9E-02
rs3184504 12:111884608 SH2B3 A G 0.53 0.51 1.1 3.9E-07 0.56 0.54 1.11 1.1E-02
rs4779584 15:32994756 G A 0.21 0.19 1.2 2.3E-18 0.22 0.19 1.22 4.4E-05
rs4939827 18:46453463 SMAD7 G A 0.57 0.52 1.2 1.3E-33 0.54 0.50 1.18 6.3E-05
rs10411210 19:33532300 RHPN2 A G 0.92 0.91 1.2 2.4E-08 0.92 0.91 1.12 1.4E-01
rs961253 20:6404281 C A 0.39 0.36 1.1 6.8E-12 0.39 0.36 1.13 2.6E-03
rs4925386 20:60921044 LAMA5 A G 0.71 0.68 1.1 8.7E-10 0.73 0.69 1.20 4.0E-05
rs78446341 2:160690656 LY75 G A 0.03 0.02 1.3 3.3E-05 0.01 0.01 1.18 3.3E-01
rs6599132 3:41039907 A G 0.57 0.55 1.1 2.5E-05 0.54 0.53 1.04 2.8E-01
rs2548145 5:40134777 A G 0.54 0.52 1.1 6.9E-05 0.52 0.52 0.97 4.1E-01
rs2282978 7:92264410 CDK6 A G 0.34 0.32 1.1 1.1E-06 0.33 0.33 1.03 4.8E-01
rs6580741 12:50727706 FAM186A C G 0.37 0.35 1.1 3.9E-05 0.34 0.32 1.10 3.3E-02
rs7296291 12:50744119 FAM186A A G 0.37 0.35 1.1 5.8E-05 0.34 0.32 1.09 4.0E-02
rs11169552 12:51155663 A G 0.75 0.73 1.1 2.6E-05 0.71 0.69 1.07 1.0E-01
rs861204 12:51237816 TMPRSS12 A G 0.67 0.66 1.1 4.2E-05 0.68 0.68 1.00 9.6E-01
rs10774625 12:111910219 ATXN2 A G 0.52 0.49 1.1 1.1E-05 0.55 0.52 1.13 2.1E-03
rs653178 12:112007756 ATXN2 G A 0.53 0.51 1.1 1.7E-06 0.56 0.54 1.12 4.7E-03
rs7315438 12:115891403 G A 0.59 0.57 1.1 3.0E-05 0.63 0.61 1.09 5.0E-02
rs11869286 17:37813856 STARD3 G C 0.34 0.32 1.1 7.3E-05 0.33 0.33 1.03 4.9E-01
rs2307019 19:49244220 IZUMO1 A G 0.59 0.58 1.1 6.1E-05 0.58 0.57 1.04 3.9E-01
rs2236200 20:60986019 C20orf151 C A 0.76 0.74 1.1 3.6E-05 0.80 0.76 1.23 2.6E-05
rs1209950 21:40173528 G A 0.43 0.41 1.1 7.3E-06 0.40 0.40 0.98 6.8E-01
https://doi.org/10.1371/journal.pone.0193547.t003
Table 4. Additional candidate risk variants located within 1 Mb from the eight original risk markers.
SNP Chromosomal
band
Position Ref
allele
Risk
allele
Gene AA change Freq in
case
Freq in
ctrl
OR P-value MAF
SweGen
MAF
1000G
MAF
ExAC
rs202114540 2p13.1 2:73677049 A G ALMS1 Q1131R 7.2E-4 0 - 3E-05 - NA 5.0E-
05
rs140849642 9q32 9:117027755 G A COL27A1 splice
region
7.2E-4 0 - 3E-05 - NA 1.8E-
04
rs201749293 20q13.12 20:43043289 G A HNF4A P212L 7.2E-4 0 - 3E-05 5E-04 NA 3.1E-
04
MAF was extracted from the SweGen (https://swegen-exac.nbis.se/), ExAC (http://exac.broadinstitute.org/) and 1000Genomes (http://www.internationalgenome.org/)
databases (date of access: 2017-07-25).
https://doi.org/10.1371/journal.pone.0193547.t004
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are prone to genotyping errors and artefacts, and in fact many more SNPs were suggested but
ruled out in our study leaving eight out of 39 from primary analysis.
Both cases and controls in this study were analyzed using Illumina Infinium BeadChip, but
on different platforms at different time points. We designed the study by only using SNPs suc-
cessfully genotyped on both genotyping platforms. In general, genotypes were called by Gen-
Call algorithm in both datasets, however, an additional algorithm zCall was integrated for rare
variant calling in the control dataset but not the case dataset. In order to eliminate false risk
variants due to incorrect calling, we sequenced all cases as carriers for the suggested risk SNPs.
Calling artefacts were observed in most of the suggested SNPs, leaving only eight (25%) sug-
gested moderate risk genetic variants validated. This implicates the challenging nature of rare
variant calling.
Accurate estimation of population allele frequency for rare variants depends particu-
larly on representative population and adequate sampling. Although combining data
could be used to reduce variance and improve estimation, pooling of samples representing
distinct populations can lead to biased estimates. Difference in MAF between European
population and all populations in the 1000Genomes [19] and ExAC [20] databases indi-
cates the divergence among populations (Table 1). The SweGen project [31] included 1
000 individuals reflecting a cross-section of the Swedish population, but its sample size
could be insufficient for estimation of rare allele frequency. In this study, we used 12 108
unaffected individuals from the Swedish Twin Registry as controls, likely providing a bet-
ter representation of the Swedish population. This could possibly explain that for some
candidate SNPs, the risk allele frequency in CRC cases is not substantially higher than that
in SweGen (Table 1).
The variant rs201302413, had the highest OR, 17.6, and was in a gene not well studied. The
gene, PABPC1L, is known to be involved in transcription and has been shown to be down-reg-
ulated by preoperative radiotherapy in rectal cancer [32]. Single cell sequencing in one CRC
showed one clone with a PABPC1 mutation together with a CDC27mutation [33].
The variant rs148220987 in the RAB11FIP5 gene had an OR of 6.3. The Rab GTPases family
regulates intracellular membrane trafficking in eukaryotic cells and is known to be involved in
cancer signaling pathways [34]. Rab11 regulates JNK and Raf/MAPK-ERK signaling pathways
[35] and Rab1 and Rab11 are playing a key role in Notch signaling via vesicular trafficking
[36]. Recent discoveries have demonstrated a family of genes downstream of the Rab GTPase,
the FIP family [37]. RAB11FIP5or Rip11, is one of them. FIP function is not well known but
shown to be involved in crucial cellular physiological processes such as cell division, and cell
migration in various human cancers [37].
The SNP rs754511 in the MYH7B gene had an OR of 3.6. This gene is not well studied in
CRC but has been studied in melanoma, and MYH7B SNPs have been associated with
increased melanoma risk [38–40]. It did not segregate well in family 340 (Fig 1).
rs200554635 in the MUC5B gene had an OR of 3.5. Stromal genes such as mucins have
been shown to affect carcinogenesis, and polymorphisms in microRNA binding sites of those
genes have been suggested to predict clinical outcome in CRC patients [41]. Mutations in gene
GALNT12 have been found in colonic cancers and also suggested to predict CRC and this
enzyme is initiating mucin type O-linked protein glycosylation and may contribute to a subset
of colon cancers [42]. Moreover, Cox2 is well known to be involved in CRC carcinogenesis
and has been suggested to act by inducing Muc5B and Muc17 secreting cells in the pathogene-
sis of esophageal cancer [43].
The SNP rs12193504 is located close to the NEU1 gene, which has been studied extensively
in cancer and suggested to have a profound effect in human cancers [44]. The gene plays a role
in sialidase-mediated regulation of tumorigenesis including growth factor receptor signaling,
Rare variants associated with Swedish CRC
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control of TOLL-like receptor signaling and immune-mediated tumorigenesis, regulation of
epithelial mesenchymal transition as well as acquired chemo-resistance and regulation of vas-
cularization [44]. NEU1 has specifically been suggested to suppress metastasis in human colon
cancer cells [45]. This NEU1 related SNP is located within transcription factor binding sites
and DNase hypersensitivity clusters, suggesting its potential regulatory function. This marker
could be tested and found in one additional patient with stomach cancer in family 1164 and in
one other CRC patient in family 275, but not in another person with a high-risk adenoma
from the same family (Fig 1).
We detected variants of rs202238834 in three of the cases, leading to an allele frequency of
0.001, which is higher than the MAF of 0.0001 from the ExAC project. None of the controls
had this variant. This variant is located in the exonic region of POTEA gene, member of a
highly homologous gene family expressed in a wide variety of human cancers (colon, lung,
breast, ovary and pancreas) [46]. Biological function of this gene family is not clear, but there
is evidence for its role in inducing programmed cell death [47].
The SNP rs34578955 has a MAF of 0.03%-0.1% in European people, compared to allele
frequency 0.14% in our cases. This SNP is within the COL27A1 gene. Collagens are stro-
mal genes known to be involved in carcinogenesis in experiment animal models [48] and
suggested to influence epithelial cells and tumor growth by influences from stromal cells
[49]. We have previously suggested that expression of COL11A1 and COL5A3 in CRCs
could be associated with CRC carcinogenesis [50, 51]. This SNP segregated in three
patients with CRC over three generations (family 1213) supporting the SNP to be involved
in all family members with CRC in this family (Fig 1). Furthermore, another variant in the
splice region was found when the locus was searched for additional markers with sugges-
tive p-value (3E-05) (Table 4).
The risk allele of rs137990346 occurred with a 0.14% frequency among our cases and none
in controls, which is reasonable considering the expected frequency in SweGen, ExAC and
1000Genomes. The SNP lies within the PSMA8 gene, a specific subunit involved in histone
acetylation and could play a critical role in chromatin remodeling, DNA repair and epigenetic
regulation of gene expression [52].
Moreover, we also searched for additional candidate markers located close to the eight risk
variants. Three more SNPs, rs202114540, rs140849642 and rs201749293 were found within 1
Mb from rs148220987, rs34578955 and rs201302413, respectively, and verified by Sanger
sequencing (Table 4). Each of these three variants was observed in two unrelated CRC cases,
but not in any controls, giving a p-value of 3E-05 which is suggestive for risk variants. SNP
rs140849642 is located in the splice region of gene COL27A1, confirming the involvement of
COL27A1, whereas markers rs202114540 and rs201749293 are in the coding regions of ALMS1
and HNF4A. Mutations in ALMS1 (centrosome and basal body associated protein) gene are
known to cause Alstro¨m’s syndrome [53, 54]. Several GWAS also reported variants in or near
ALMS1 to be associated with chronic kidney disease [55, 56]. HNF4A (hepatocyte nuclear fac-
tor 4 alpha) encodes a nuclear transcription factor regulating metabolism, cell junctions, dif-
ferentiation and proliferation in liver and intestinal epithelial cells. Expression profile of its
isoforms has been demonstrated modified in many cancers including CRC [57], and it was
implicated that the interaction between Src tyrosine kinase and HNF4α has important implica-
tions for colon and other cancers [58].
In conclusion, we suggested eight novel candidate CRC risk loci, within the Swedish popu-
lation. The study suggest that low frequent risk alleles contribute to the risk of cancer in seem-
ingly high-risk families and also that the total risk in these families are contributed by more
than one risk factor such as in complex disease.
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Supporting information
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